Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Cancer Research - United States
doi 10.1158/0008-5472.can-16-0396
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas

Oncotarget
Oncology
2016English

Dissecting Mechanisms of Resistance to Targeted Drug Combination Therapy in Human Colorectal Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2019English

Emergence of KRAS Mutations and Acquired Resistance to Anti-Egfr Therapy in Colorectal Cancer

Nature
Multidisciplinary
2012English

mTORC1/autophagy-regulated MerTK in Mutant BRAFV600 Melanoma With Acquired Resistance to BRAF Inhibition

Oncotarget
Oncology
2017English

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2015English

Author Correction: PAK Signalling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas

Nature
Multidisciplinary
2018English

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2012English

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2019English

Targeted Therapy for Patients With BRAF-Mutant Lung Cancer Results From the European EURAF Cohort

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy